Viragen, Inc. announced that the company has initiated its Multiferon marketing and sales program in Mexico with the natural human alpha interferon drug being shipped to its distributor, Laboratorios Pisa. As part of the product’s launch, a presentation was made on February 14th at the Mexican National Oncology Congress in Veracruz that discussed the merits of Multiferon as an adjuvant treatment for malignant melanoma, a potentially lethal skin cancer.

“Our Multiferon marketing team has been working closely with our strategic partner, Laboratorios Pisa, to commence with our marketing and sales program in Mexico and we are pleased to report that we have shipped an initial order,” stated Viragen’s executive vice president, Mel Rothberg. “As part of this campaign, Laboratorios Pisa sponsored a Multiferon presentation at an important Mexican National Oncology Congress sponsored by the National Cancer Institute (INCAN) that discussed the drug’s potential to treat malignant melanoma. Moving forward, we will target the treatment of a variety of viral and malignant diseases including hepatitis B, hepatitis C and certain cancers.”

At a plenary session of the Mexican National Oncology Congress, professor Örjan Strannegård from Göteborg University in Sweden made a presentation titled, “Adjuvant treatment of malignant melanoma with natural interferon alpha.” Dr Strannegård serves as a director for ViraNative AB, Viragen’s Swedish interferon manufacturing subsidiary.

Dr Jorge Yoma, medical director for Laboratorios Pisa, commented, “Our feedback from the Congress was very encouraging. We believe that Multiferon is the first natural human alpha interferon that can be priced competitively with recombinant versions, so we are making a very strong case supporting its use to physicians and patients seeking an alternative interferon therapy.”